secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-08-31T10:01:33+00:00
Accession:  0001193125-26-375275
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin settles patent disputes with Ascendis; gets 20% US royalty on Yuviwel sales
--------------------------------------------------------------------------------

- Ascendis pays 20% of US net sales and 18% of EU/Brazil/South Korea net sales, retroactive to first commercial sale, until May 2030.
- BioMarin grants non-exclusive worldwide license to its CNP patents for Yuviwel (navepegritide) across all indications, incl. achondroplasia.
- All pending litigation dismissed with prejudice, including ITC Section 337 investigation and cases in Brazil, Denmark, Germany, South Korea, and N.D. Cal.
- Binding term sheet signed Aug 30, 2026; parties to finalize definitive agreement by Sept 24, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526375275/0001193125-26-375275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526375275/d110137d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-375275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer